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870-3 Metalloproteinase Inhibition Prevents Diastolic 
Stiffening, AMP-Breakdown, and Oxypurine 
Accumulation in Accelerated Heart Failure
Nazareno Paolocci, Barbara Tavazzi, Roberto Biondi, Yehezkiel A. Gluzband, Mariangela 
Amorini, Carlo G. Tocchetti, Sonia Donzelli, Michael T. Crow, Giuseppe Lazzarino, David 
A. Kass, Johns Hopkins Medical Institutions, Baltimore, MD, University of Catania, 
Catania, Italy
Background: Recent studies indicated increased plasma oxypurine (hypoxanthine/xan-
thine/uric acid) levels as an independent risk factor for worsened heart failure, suggesting
oxypurine potential role for diastolic dysfunction.
Methods: We used a canine model of enhanced diastolic failure (1 week AII infusion +
subacute tachypacing; 250 bpm for 48 hrs; AII+P), displaying pronounced diastolic stiff-
ening and marked metalloproteinase (MMP) activation. MMP inhibition (MMPI) prevents
diastolic stiffening, without influencing collagen content/subtype or cross-linking. Here we
tested whether AII+P (n=7) enhances AMP catabolism to increase cardiac nucleoside/
oxypurine and diastolic stiffening, assessing the ability of MMPI to prevent these
changes.
Results: AII+P raised diastolic chamber stiffness and end-diastolic pressure ~100% and
markedly activated gelatinases MMP-9 and MMP-2 (abundance and in situ assays). With
AII+P, ATP declined while AMP catabolites increased: nucleotides (inosine, adenosine)
raised from 254±94 to 1700± 363nmol/g (p<0.005), and oxypurines from 100±20 to 666±
67 nmol/g (p<0.001). MMP inhibition (PD-166793, 5 mg/kg/day, n=9) prevented diastolic
stiffening as well as MMP-9 and -2 activation, and countered the rise in both nucleotides
(804± 35 nmol/g, p<0.02 vs AII-P) and oxypurines (397± 17, p<0.001 vs AII-P). MMPI
directly inhibited in vitro AMP deaminase activity in a dose-dependent manner but did not
affect other steps of the purine catabolism cascade. In AII+P hearts hallmarks of oxida-
tive stress were evident: malondialdehyde (lipid peroxidation index) raised from 0.31±0.1
(controls) to 6.7±2.3 nmol/g (p<0.01) while antioxidant levels (ascorbate and reduced
glutathione) significantly declined. However, MMPI did not mitigate AII+P-induced oxida-
tive stress (MDA = 6.1±1.3).
Conclusions: Diastolic stiffening is associated with a rise in myocardial content of AMP-
breakdown byproducts (i.e. nucleosides and oxypurines). MMP inhibition fully prevents
diastolic stiffening by limiting this accumulation, direcly interfering with AMP catabolic
activities (i.e.AMP deaminase), independently from the extent of cardiac oxidative stress.
9:15 a.m.
870-4 Survival, Differentiation, and Contractility of Immature 
Cardiac Cells Implanted Into the Outer Wall of Aorta in 
Rats as a Step in the Development of an Auxiliary 
Circulatory Pump
Wangde Dai, Sharon Hale, Robert A. Kloner, The Heart Institute, Good Samaritan 
Hospital, University of Southern California, Los Angeles, CA
Purpose: We proposed to build an auxiliary circulatory pump by implanting neonatal car-
diac cells into the wall of aorta in rats. As a first step, we investigated the survival, differ-
entiation and contractility of immature cardiac cells implanted into the wall of the
abdominal aorta.
Methods: Cardiomyocytes from neonatal Fischer rats (both sexes) were injected into the
outer wall of the abdominal aorta at a site 3 mm above the take-off of the renal arteries in
female Fischer rats. Rats were divided into 2 groups: (1) medium only (n=22); (2) neona-
tal cardiomyocytes (n=22, 5×106 cells each). At 2 or 6 weeks, the grafted site on the
aorta was exposed and fixed for histological and immunohistologic examination.
Results: At 2 weeks after transplantation, 7 out of 10 aortas in the cell group, but none of
10 in the medium group showed spontaneous rhythmic beating at the grafted site follow-
ing excision of the heart. The intra-aortic pressure was comparable between the cell
group and the medium group after the aorta was clamped at its origin (2.88 ± 0.45 vs
2.94 ± 0.63 mmHg, p= 0.94). Pacing in a cell grafted aorta increased aortic pressure 5
fold from baseline. PCR of the SRY gene to identify male cells was positive in 3 examined
aortas in the cell group confirming presence of transplanted cells and none of 3 aortas in
the medium group at 6 weeks. Hematoxylin and eosin staining showed viable grafts in
the outer wall of the cell-treated aortas in 9 out of 10 aortas at 2 weeks and 9 out of 9 aor-
tas at 6 weeks; and none of the aortas receiving medium at 2 (n=10) or 6 weeks (n=9).
Neonatal cardiomyocytes in the graft formed compact, longitudinally oriented cardiac
muscle bundles, and were differentiated with cross strations and a high degree of vascu-
larization. Immunohistochemical staining for sacromeric actin was positive in 4 out of 10
aortas at 2 weeks and 9 out of 9 aortas at 6 weeks in the cell group; and none of the aor-
tas in the medium group.
Conclusion: The results show that grafted neonatal cardiomyocytes survive, differenti-
ate, develop a blood supply and spontaneously contract within the outer wall of the aorta
in rats. It is feasible to transplant immature cardiac cells into the aorta to fashion an exter-
nal auxiliary circulatory pump.
9:30 a.m.
870-5 Uncovering Human Cardiac Myocyte Progenitor Cells 
for Myocardial Regeneration
Lincoln T. Shenje, Bashir M. Matata, Manuel Galiñanes, University of Leicester, 
Leicester, United Kingdom
Background: The failure to identify and culture human cardiac progenitor cells has rein-
forced the idea that the heart is a terminally differentiated organ, with little or no capacity
for self renewal. Increasing evidence suggests baseline levels of myocyte loss in the
human myocardium require sustainable myocyte renewal for cardiac homeostasis. We
investigated whether cardiac progenitor cells can be cultured from the human myocar-
dium.
Methods: Cells derived from cultured human right atrial tissue explants (RATEs) were
depleted of fibroblast surface antigen (FSA) positive cells using immunomagnetic beads.
The resultant FSA negative fraction was assessed for cells expressing markers of car-
diac differentiation using flow cytometry and confocal microscopy as well as for stem cell
markers and the cell cycle antigen Ki-67.
Results: Human atrial myocardial tissue explants produce a heterogeneous cell popula-
tion amongst which are small highly proliferating cells, expressing markers of cardiac dif-
ferentiation; Csx/Nkx-2.5, GATA-4, alpha-sarcomeric actinin, cardiac myosin heavy chain
together with the cell cycle antigen Ki-67. In addition the cells also express c-Kit and
MDR-1 denoting stem cell properties. At 9-12 weeks in culture they fuse to form rod like
multinucleate cells similar to those previously described as myotubes.
Conclusions: Our study shows for the first time that there is a potential for self renewal
of the human myocardium involving cardiac progenitor cells and that cardiac stem cells
can be cultured. This has major implications in the study of stem cell biology and the
development of cell therapy for myocardial regeneration.
9:45 a.m.
870-6 The Role of Angiopoietin-1 in Physiologic and 
Pathologic Cardiac Remodeling and in Promoting 
Cardiac Myocyte Survival
Susan Marie Dallabrida, Michelle Euloth, Maria Ann Rupnick, Children's Hospital, 
Boston, MA, Harvard Medical School Affiliate, Boston, MA
Background: Cardiac remodeling contributes to cardiovascular disease progression,
emerging as a therapeutic target for heart failure.While remodeling initially compensates
for injured myocardium, it is a progressive process that is ultimately maladaptive. Under-
standing processes resulting in adaptive growth are needed. In development, the heart
grows and remodels via increases in myocytes (hypertrophy, hyperplasia) and capillaries
(angiogenesis). We propose angiopoietin-1 (ang1), a vascular maturation factor, is a
mediator of cardiovascular remodeling. Ang1 is required for cardiac development and
increases in hypoxic myocardium. Ang1's receptor, tie2 is endothelial-specific, so its role
is thought to be limited to vessels. A recent study shows that ang1 binds integrins, per-
haps revealing new roles for ang1 in cardiac development and remodeling.
Methods: We measured ang1, ang2, and tie2 mRNA levels in developing/adult hearts
(fetal, 1, 2, 4, 7, 14, 21, 56, 133, 238 d) and thyroid hormone (T3)-induced cardiac hyper-
trophy (1-4, 7, 14 d) using C57BL/6 mice, and in neonatal/adult cardiac myocytes and a
cardiac myocyte cell line (C2C12) (real-time RT-PCR). We compared ang/tie in the left
ventricle (LV), right ventricle (RV), and atria (AT) (in vivo studies). We examined if ang1
binds (cell adhesion) and promotes cardiac myocyte survival/proliferation using in vitro
studies (C2C12 cells).
Results: Ventricular and atrial ang1 levels increase in the fetal to adult transition. Ang1
increases (LV=475, RV=75, AT=4 fold) are related to the extent that the chamber mass
increases. Ang1 was undetectable in neonatal, but prominent in adult cardiac myocytes.
T3-induced cardiac hypertrophy increases LV ang1 up to 20 fold. Cardiac myocytes bind
ang1. Ang1 markedly promotes myocyte survival and proliferation in serum-free media (7
d versus controls < 1 d) with the number of surviving cells declining from 7-21 d.
Conclusion: Our studies support a role for ang1 in physiologic and pathologic cardiovas-
cular remodeling. They identify a mechanism for enabling myocyte survival/proliferation
in adverse conditions, and have broad implications for cardiac hypertrophy/heart failure
therapy development.
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872-1 Reverse Remodeling With Cardiac Resynchronization 
Therapy Varies With Infarct Location: Analysis of 
Echocardiographic Data From the MIRACLE Trial
Martin St. John Sutton, Ted Plappert, Thomas J. Mullen, Kathyrn Hilpisch, Edward 
Chinchoy, University of Pennsylvania Medical Center, Philadelphia, PA, Medtronic, Inc, 
Minneapolis, MN
Reverse remodeling has been reported in moderate to severe heart failure (HF) patients
(pts) with ventricular dysynchrony after cardiac resynchronization therapy (CRT). This
analysis assessed whether infarct location predicted the degree of reverse remodeling
after 6 months of CRT. METHODS: The MIRACLE study enrolled NYHA Class III/IV HF
pts with ventricular dysynchrony and LVEF<35%. All pts were implanted with an InSync
atrial synchronous biventricular pacing system. AV delay was individually optimized and
pts were randomized to no pacing (control) or to CRT. Doppler echocardiograms were
analyzed by a core laboratory. Left ventricular end diastolic volume (LVEDV), LV end sys-
tolic volume (LVESV), LV ejection fraction (LVEF), and mitral regurgitation color flow jet
area (MR) were calculated. Infarct location was determined using a 16 segment model.
Anterior infarction (AMI) was defined as akinesis in at least 3 antero-apical segments and
inferior infarction (IMI) defined as akinesis in at least 3 postero-inferior segments.
Changes in LV remodeling were quantified and compared between the AMI and IMI
groups after 6 months of CRT. RESULTS: Significant reductions in LVEDV and LVESV
